JP2022506781A5 - - Google Patents
Info
- Publication number
- JP2022506781A5 JP2022506781A5 JP2021524371A JP2021524371A JP2022506781A5 JP 2022506781 A5 JP2022506781 A5 JP 2022506781A5 JP 2021524371 A JP2021524371 A JP 2021524371A JP 2021524371 A JP2021524371 A JP 2021524371A JP 2022506781 A5 JP2022506781 A5 JP 2022506781A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- hla
- acid sequence
- seq
- sequence shown
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862758397P | 2018-11-09 | 2018-11-09 | |
| US62/758,397 | 2018-11-09 | ||
| PCT/US2019/060570 WO2020097530A2 (en) | 2018-11-09 | 2019-11-08 | Immunotherapy targeting mesothelin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022506781A JP2022506781A (ja) | 2022-01-17 |
| JP2022506781A5 true JP2022506781A5 (cg-RX-API-DMAC7.html) | 2022-11-16 |
| JP7558935B2 JP7558935B2 (ja) | 2024-10-01 |
Family
ID=69160156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524371A Active JP7558935B2 (ja) | 2018-11-09 | 2019-11-08 | メソテリンを標的とする免疫療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12595290B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3877404A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7558935B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20210102231A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113286815B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019377553A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021008973A8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3119188A1 (cg-RX-API-DMAC7.html) |
| EA (1) | EA202191012A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL282926A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021005308A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202104349QA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020097530A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022040454A1 (en) * | 2020-08-20 | 2022-02-24 | A2 Biotherapeutics, Inc. | Compositions and methods for treating mesothelin positive cancers |
| WO2022232599A1 (en) * | 2021-04-30 | 2022-11-03 | Regents Of The University Of Minnesota | Mesothelin-specific t cell receptors and methods of using same |
| WO2025245169A1 (en) | 2024-05-21 | 2025-11-27 | Fred Hutchinson Cancer Center | Immunotherapy cells equipped with a collagen-targeting payload |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US8206965B2 (en) | 2002-03-15 | 2012-06-26 | Cellectis S.A. | Hybrid and single chain meganucleases and use thereof |
| US20060206949A1 (en) | 2003-01-28 | 2006-09-14 | Sylvain Arnould | Custom-made meganuclease and use thereof |
| WO2006076678A2 (en) | 2005-01-13 | 2006-07-20 | The Johns Hopkins University | Prostate stem cell antigen vaccines and uses thereof |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| KR101773690B1 (ko) * | 2007-03-05 | 2017-08-31 | 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 | 암 항원 특이적 t 세포의 수용체 유전자 및 그것에 따라 코드되는 펩티드 및 이들의 사용 |
| EP2210903A1 (en) | 2009-01-21 | 2010-07-28 | Monoclonal Antibodies Therapeutics | Anti-CD160 monoclonal antibodies and uses thereof |
| EP2258719A1 (en) | 2009-05-19 | 2010-12-08 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Multiple target T cell receptor |
| AU2011256838B2 (en) | 2010-05-17 | 2014-10-09 | Sangamo Therapeutics, Inc. | Novel DNA-binding proteins and uses thereof |
| US9676854B2 (en) | 2011-08-15 | 2017-06-13 | Medimmune, Llc | Anti-B7-H4 antibodies and their uses |
| ES2728782T3 (es) | 2012-05-25 | 2019-10-28 | Univ California | Métodos y composiciones para la modificación de ADN objetivo dirigida por ARN y para la modulación de la transcripción dirigida por ARN |
| EP3064585B1 (en) | 2012-12-12 | 2020-02-05 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2013361275B2 (en) | 2012-12-19 | 2016-11-24 | Amplimmune, Inc. | Anti-human B7-H4 antibodies and their uses |
| EP3760719A1 (en) | 2013-11-18 | 2021-01-06 | CRISPR Therapeutics AG | Crispr-cas system materials and methods |
| CN122399016A (zh) * | 2014-03-15 | 2026-07-17 | 诺华股份有限公司 | 使用嵌合抗原受体治疗癌症 |
| CN106459165B (zh) * | 2014-04-01 | 2021-04-20 | 拜恩科技细胞&基因治疗有限公司 | 密封蛋白-6特异性免疫受体和t细胞表位 |
| TW201625689A (zh) | 2014-09-12 | 2016-07-16 | 建南德克公司 | 抗-b7-h4抗體及免疫結合物 |
| US10577417B2 (en) * | 2014-09-17 | 2020-03-03 | Novartis Ag | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| RU2017115315A (ru) | 2014-10-03 | 2018-11-08 | Дана-Фарбер Кэнсер Инститьют, Инк. | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения |
| IL254039B2 (en) | 2015-02-19 | 2023-12-01 | Compugen Ltd | Anti-pvrig antibodies and methods of use |
| JO3620B1 (ar) | 2015-08-05 | 2020-08-27 | Amgen Res Munich Gmbh | مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم |
| WO2017112944A1 (en) * | 2015-12-23 | 2017-06-29 | Fred Hutchinson Cancer Research Center | High affinity t cell receptors and uses thereof |
| WO2017192924A1 (en) | 2016-05-04 | 2017-11-09 | Fred Hutchinson Cancer Research Center | Cell-based neoantigen vaccines and uses thereof |
| KR102397771B1 (ko) | 2016-09-23 | 2022-05-13 | 프레드 헛친슨 켄서 리서치 센터 | 부 조직적합성(h) 항원 ha-1에 대해서 특이적인 tcr 및 이의 용도 |
| WO2018129270A1 (en) * | 2017-01-05 | 2018-07-12 | Fred Hutchinson Cancer Research Center | Systems and methods to improve vaccine efficacy |
-
2019
- 2019-11-08 JP JP2021524371A patent/JP7558935B2/ja active Active
- 2019-11-08 US US17/291,985 patent/US12595290B2/en active Active
- 2019-11-08 EA EA202191012A patent/EA202191012A1/ru unknown
- 2019-11-08 EP EP19836121.4A patent/EP3877404A2/en active Pending
- 2019-11-08 MX MX2021005308A patent/MX2021005308A/es unknown
- 2019-11-08 CN CN201980088274.1A patent/CN113286815B/zh active Active
- 2019-11-08 AU AU2019377553A patent/AU2019377553A1/en not_active Abandoned
- 2019-11-08 SG SG11202104349QA patent/SG11202104349QA/en unknown
- 2019-11-08 KR KR1020217016825A patent/KR20210102231A/ko active Pending
- 2019-11-08 CA CA3119188A patent/CA3119188A1/en active Pending
- 2019-11-08 WO PCT/US2019/060570 patent/WO2020097530A2/en not_active Ceased
- 2019-11-08 BR BR112021008973A patent/BR112021008973A8/pt unknown
-
2021
- 2021-05-04 IL IL282926A patent/IL282926A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rosenberg | Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens | |
| Criscitiello | Tumor-associated antigens in breast cancer | |
| Lee et al. | DNA vaccines, electroporation and their applications in cancer treatment | |
| Zhou et al. | Breast cancer immunotherapy | |
| Tsuboi et al. | Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A* 2402-binding residues | |
| ES2676630T3 (es) | Control inmunogénico de tumores y células tumorales | |
| Baxevanis et al. | Immunogenic HER-2/neu peptides as tumor vaccines | |
| CN105622749B (zh) | 癌抗原辅助肽 | |
| JP2022525099A5 (cg-RX-API-DMAC7.html) | ||
| Jäger et al. | Vaccination for malignant melanoma: recent developments | |
| ES2652017T3 (es) | Métodos y composiciones farmacéuticas para el engaño inmunitario, particularmente útiles en el tratamiento de cáncer | |
| AU2017275782A1 (en) | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer | |
| KR101454935B1 (ko) | 면역치료용 크립틱 hla-b7 에피토프의 동정, 최적화 및 용도 | |
| Wang et al. | Enhancing the immune response and tumor suppression effect of antitumor vaccines adjuvanted with non-nucleotide small molecule STING agonist | |
| AR110857A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer | |
| CN117187185A (zh) | 一种工程化免疫细胞及其用途 | |
| Harada et al. | Target molecules in specific immunotherapy against prostate cancer | |
| JP2022547809A5 (cg-RX-API-DMAC7.html) | ||
| JP2025509573A (ja) | 組換え融合タンパク質の組成物及びcar免疫細胞を作製するためのその使用方法 | |
| RU2022100330A (ru) | Пептид, полученный из depdc1, и содержащая его вакцина | |
| CA2634480C (en) | Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof | |
| Velders et al. | Identification of peptides for immunotherapy of cancer. It is still worth the effort | |
| Smith et al. | Immunotherapy of colorectal cancer | |
| JP2020529847A5 (cg-RX-API-DMAC7.html) | ||
| McKee et al. | T cell immunotherapy |